A retrospective study of BRAF inhibitors and EGFR inhibitors combined with immune checkpoint inhibitors in patients with microsatellite stable, BRAF V600E mutated metastatic colorectal cancer
10.3760/cma.j.cn112152-20250101-00002
- VernacularTitle:BRAF抑制剂及EGFR抑制剂联合免疫检查点抑制剂在微卫星稳定、BRAF V600E突变转移性结直肠癌患者中的回顾性研究
- Author:
Zhi JI
1
;
Jinguo MA
;
Xia WANG
;
Jiaqi XIN
;
Lijun MA
;
Yixuan WANG
;
Nan ZHANG
;
Chunyan ZENG
;
Rui LIU
Author Information
1. 国家恶性肿瘤临床医学研究中心 天津市恶性肿瘤临床医学研究中心 天津市消化系统肿瘤重点实验室 天津医科大学肿瘤医院消化肿瘤内科，天津 300060
- Publication Type:Journal Article
- Keywords:
Colorectal neoplasms;
RAF V600E;
Targeted therapy;
Immunotherapy
- From:
Chinese Journal of Oncology
2025;47(9):922-928
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacy and safety of B-Raf proto-oncogene, serine/threonine kinase (BRAF) inhibitor and epidermal growth factor receptor (EGFR) inhibitor combined with immune checkpoint inhibitor in microsatellite stable (MSS) BRAF V600E metastatic colorectal cancer (mCRC) patients.Methods:The data and outcomes of mCRC patients with MSS BRAF V600E who received BRAF inhibitor, EGFR inhibitor combined with immune checkpoint inhibitor in Tianjin Medical University Cancer Hospital from May 2022 to April 2024 were retrospectively collected.Results:A total of 12 mCRC patients were included in this study, the objective response rate was 50.0%, the disease control rate was 66.7%, and the median disease control time of patients who achieved objective response was 8.0 months. The median progression-free survival was 6.8 months and the median overall survival was 8.4 months. Overall adverse reactions were controllable, the most common treatment-related adverse events were fatigue (8 cases), fever (5 cases), and rash (4 cases). There were no grade 4 adverse event, serious adverse event, and treatment-related death.Conclusion:BRAF inhibitor and EGFR inhibitor combined with immune checkpoint inhibitor show good efficacy and controllable safety in BRAF V600E mCRC patients.
